Ansell (ASX.ANN) is experiencing good sales growth this year, driven by the US. Positive EBIT margin growth is supported by operational and supply chain improvements. The company maintained adjusted fiscal 2027 EPS guidance of USD 1.58 to USD 1.70.

Why it matters: We maintain our fiscal 2027 adjusted EPS forecast of USD 1.65, unchanged at about the midpoint of guidance.

  • We estimate sales growth of 6% in healthcare, driven by entry into higher-growth niche categories, in addition to an aging population and increased medical intervention as people live longer, and 4% in industrials, supporting manufacturing industry growth and a global focus on safety in the workplace.
  • The trading update was vague and had little specific detail on revenue growth. However, the US manufacturing purchasing managers index indicates growth over the fiscal year thus far, so we expect both businesses are contributing to current sales growth, despite industrials having more cyclical exposure than healthcare.

The bottom line: Shares in no-moat Ansell are expensive compared with our unchanged $35 fair value estimate. We think the market is likely anticipating the company to maintain higher revenue and EBIT margin growth than we do.

  • Shares are trading at a historic high. While we disagree with the market on valuation, we think there is a lot to like about Ansell, with its strong brand name and trustworthiness supporting sales and its specialized products in niche healthcare categories supporting operating margin growth.
  • Ansell has low capital intensity, with capital expenditure averaging about 2% of sales over our explicit forecast period. We expect investment to support high-growth sectors like clean room, where prices and margins can be higher due to product specialization and less competition.

Mix shift to higher-margin healthcare sales underpins EBIT margin growth

Ansell’s strategic focus is on growing market share in niche markets across industrial and healthcare settings. We think this strategy is appropriate, given a less competitive environment in niche markets, where product innovation and regulatory requirements raise barriers to entry, and an ability to achieve better margins from these sales.

Each market is reasonably fragmented, and Ansell’s market share varies by subsegment, but it has consistently held the highest or second-highest global market share in its key product categories. Main competitors are Honeywell (PIP), 3M, and Globus (UK) in industrial, and Cardinal Health, Honeywell, and Halyard Health (Owens & Minor) in healthcare.

Revenue is split approximately 50/50 between healthcare and industrial products. Industrial is exposed to global manufacturing cycles, and the US purchasing managers’ index is a key leading indicator of Ansell’s industrial revenue growth. Revenue from the healthcare segment is more defensive, with low cyclical exposure.

We estimate the global protective wear market to grow in the low single digits, driven by the positive trends toward improved workplace safety, but partially offset by increasing automation. Growth opportunities include emerging markets, where users are shifting from commoditized products to niche alternatives.

In the midterm, we expect capital investment to be weighted toward the healthcare segment to support its higher-growth businesses. Clean room and surgical are fast-growing categories where contamination prevention is critical. We observe that Ansell is one of only a few players serving the clean room niche, with its market share position cemented by the Kimberly-Clark PPE acquisition in 2024. We estimate clean room and surgical contributing about 30% of midcycle sales.

Ansell’s margins are sensitive to key input prices, including yarn, butadiene for nitrile rubber gloves, and natural rubber for latex gloves. The approximately five-month lead time from raw material procurement to product sale provides Ansell with a window to pass through increases in input costs, if necessary, and the company has historically been able to do so.

Bulls Say

  • Expansion in clean room and surgical, a niche where Ansell’s products are more differentiated, earns materially higher margins than its other businesses, supporting group margin growth.
  • Ansell has demonstrated good capital allocation skills and has successfully integrated acquisitions and consolidated the product portfolio into key brands.
  • The company has balance sheet capacity for acquisitions and share buybacks, both of which could enhance shareholder returns.

Bears Say

  • Cost pressures such as tariffs and supply chain disruptions weigh on operations, without certainty that price pass-throughs will succeed.
  • Ansell sells primarily through distributors, where it is one of many glove suppliers in some categories. This limits its visibility into and influence over end-customer purchasing decisions.
  • Although Ansell is a leading supplier by market share, it still competes with many large competitors with reputable brands, that could take market share through new products or targeting the same customers.

Subscribe to get Morningstar insights in your inbox